OpGen Collaborates With QIAGEN to Advance Rapid Diagnostics for Antimicrobial Resistant Bacteria
October 31 2018 - 7:30AM
OpGen, Inc. (NASDAQ: OPGN) today announced a collaboration with
QIAGEN N.V. to advance rapid diagnostics for antimicrobial
resistance (AMR). Strengthening OpGen’s entry into the United
States market, the companies have entered into an agreement to
commercialize a new solution for the detection of multidrug
resistant bacterial pathogens based on QIAGEN’s EZ1 Advanced XL
automated nucleic acid purification instrumentation (EZ1) and kits
for the United States. The EZ1 will be utilized in the test
workflow for the Acuitas® AMR Gene Panel u5.47 products. The AMR
Gene Panel family of rapid diagnostics tests has been designed to
detect and identify multidrug-resistant bacterial pathogens in
urine and bacterial isolates in approximately two hours. The test
was developed for use with the Acuitas Lighthouse® Software for
predicting antibiotic resistance and high-resolution pathogen
tracking. The AMR Gene Panel u5.47 and the Acuitas Lighthouse
Software are currently available for Research Use Only (RUO).
Under the terms of the agreement, OpGen will purchase EZ1
instruments and reagent kits from QIAGEN and sell or place them
with customers in the United States for use with the Acuitas AMR
Gene Panel. The EZ1 is a Class I Medical Device listed with the
Food and Drug Administration (FDA) that provides full automation
with sample preparation throughput of up to 14 samples per one-hour
run. QIAGEN is the global leader for nucleic acid sample
preparation with a full line of instruments and reagents including
the EZ1, the QIAcube, and the QIAsymphony fully integrated
automation. There are thousands of EZ1 instruments currently used
in laboratories worldwide.
“We are pleased to collaborate with QIAGEN to further strengthen
our AMR Gene Panel offering,” said Evan Jones, Chairman and CEO of
OpGen. “The EZ1 provides best in class nucleic acid purification
technology, and QIAGEN’s extensive global commercial capabilities
and diagnostic expertise should provide multiple opportunities for
collaboration in the future.”
“We are pleased that OpGen is incorporating the EZ1 as part of
their AMR Gene Panel test offering,” said Thierry Bernard, SVP
Molecular Diagnostics Business Area, QIAGEN. “The partnership
further expands the menu for EZ1 and adds a new and rapid
diagnostic solution in the crucial fight against AMR.”
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic
analysis to provide complete solutions for patient, hospital, and
network-wide infection prevention and treatment. For more
information, please visit www.opgen.com.
OpGen, Acuitas, Acuitas Lighthouse, and QuickFISH are
registered trademarks of OpGen, Inc.
The Acuitas AMR Gene Panel u5.47 (RUO) and the Acuitas
Lighthouse Software (RUO) are intended for Research Use Only and
are not for use in diagnostic procedures. The Acuitas Lighthouse
Software is not distributed commercially for antibiotic resistance
prediction and is not for use in diagnostic procedures.
OpGen Forward-Looking
Statements
This press release includes statements relating to OpGen’s
reseller agreement with QIAGEN. These statements and other
statements regarding OpGen’s future plans and goals constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, our ability to successfully
complete the pilot portion of this project, the rate of adoption of
our products and services by hospitals and other healthcare
providers, the effect on our business of existing and new
regulatory requirements, and other economic and competitive
factors. For a discussion of the most significant risks and
uncertainties associated with OpGen's business, please review our
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which are based on our expectations as of the date of
this press release and speak only as of the date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
OpGen Contact: Michael Farmer Vice President,
Marketing (240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Investor Contacts: LHA Investor Relations Kim
Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com or Bruce Voss
(310) 691-7100 bvoss@lhai.com
Media contact:Matt BretziusFischTank Marketing
and PRmatt@fischtankpr.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024